🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Investigational Treatment Gaining Traction Via Social Media

The experimental drug, which is still in research studies, is being promoted by online personalities for its supposed weight-reducing properties. Followers are urged to contact these accounts privately for source information, while also obtaining discount codes.

Thriving Trade on Social Networks

Separately, a flourishing market exists on Telegram, where communities with numerous of participants share “before and after” images, administration instructions and claims of rapid UK delivery. Vendors promote the substance there before directing customers to other platforms for transactions.

Learning About Retatrutide

This medication is an experimental injectable developed by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could help individuals lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed online as the next Ozempic.

Medical Experts Voice Concerns

However, physicians and chemists have warned that the sale of what is still an unlicensed medication in the UK is worrisome and could result in users administering products of unknown origin.

Several experts said the demand for the experimental drug could be connected to the increasing cost of approved slimming treatments such as Mounjaro.

Legal Status and Implementation

Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some content creators try to circumvent the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted drug, but promotion and distribution can still breach medicines, marketing, and customer regulations, risking penalties, legal action or prison.

Platform Reaction and Content Removal

According to the social media company, the service has taken down violative content and banned associated hashtags and search suggestions. The company said it was committed to maintaining the service secure and allocating resources in enhancing compliance measures.

Digital Marketplace Operations

Investigations also discovered communities with up to 9,000 members marketing the experimental drug using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately displays channels with thousands of members, populated with images of weight loss, positive reviews and step-by-step instructions for mixing or administering at home.

After minutes of joining one group, a vendor shared contact information, where most transactions occur. The seller sent an guidebook and guaranteed shipping within two days. When asked whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, health issues or past usage.

Item Information and Costs

Inside these groups, messages show black plastic parcels with postal service stickers, stating to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When asked how long a injector should last, sellers give contradictory responses ranging from a several days to “depends on your body”.

Service Moderation and Security Actions

A representative for Telegram said it actively monitored harmful content on its service including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Cautions

“People are administering materials they cannot confirm. Even if the research behind this drug is sound, these online products may not contain what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service connected the surge in demand to current price rises for approved slimming medications such as Mounjaro. “With costs rising, patients are using online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already encountered individuals injured by personal administration from unconfirmed suppliers. “We understand the disappointment, but buying from Telegram or WhatsApp is gambling with your health,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly stated the substance was in third stage clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for human use,” they explained, noting that any product “falsely representing itself as a company experimental substance not yet approved … may subject patients to possibly serious health risks”.